Total synthesis and structural modification of the dibenzylbutane lignan LCA as a potent anti-inflammatory agent against LPS-induced acute lung injury
Juan Zhang,Zhen Wang,Jing Wang,Xiaobin Zhuo,Luyao Yu,Ting Han,Yan Song,Conghao Gai,Yan Zou,Qingguo Meng,Xiaoyun Chai,Qingjie Zhao
DOI: https://doi.org/10.1016/j.ejmech.2024.116272
IF: 7.088
2024-02-22
European Journal of Medicinal Chemistry
Abstract:Acute lung injury (ALI) is a serious public health problem associated with high morbidity and mortality. However, few efficacious drugs are clinically available. Inhibition of proinflammatory cytokines is considered to be a promising method for the treatment of inflammatory diseases. Herein, the total synthesis of a dibenzylbutane lignan, 9′- O -di-(E)-feruloyl- meso -5,5′-dimethoxysecoisolariciresinol (LCA), was completed. A series of LCA derivatives were designed and synthesized, and their anti-inflammatory activities were evaluated. Derivative 14r significantly inhibited lipopolysaccharide (LPS)-induced expression of nitric oxide and the proinflammatory cytokines tumor necrosis factor-α, interleukin (IL)-6, and IL-1β in RAW 264.7 cells and inhibited activation of the nuclear factor-kappa B pathway. Compound 14r reduced LPS-induced pulmonary inflammation and ALI in mice. It showed significant protective effects against LPS-induced ALI in mice and significantly reduced levels of proinflammatory cytokines in serum and bronchoalveolar lavage fluid. The ratio of wet weight to dry weight of lung tissue was normalized by compound 14r , which was consistent with suppression of neutrophil infiltration and production of proinflammatory cytokines. Compound 14r reduced the mRNA expression of some proinflammatory cytokines, improved histopathologic changes, and reduced macrophage infiltration in lung tissues. Collectively, these results suggest a new series of LCA derivatives that could be promising anti-inflammatory agents for ALI treatment.
chemistry, medicinal